氏名：相原智彦（AIHARA TOMOHIKO）

学位：医学博士（M.D., Ph.D.）

出生地：徳島

生年月日：昭和４１年７月８日（１９６６年）

国籍：日本

所属：医療法人啓明会　相原病院　乳腺科

〒562-0004　箕面市牧落3-4-30

TEL：(072)723-9000FAX:(072)723-9052

E-mail:aiharat@aiharabreast.com

学歴：

1991年　大阪大学医学部医学科卒業、医師免許取得

1999年　大阪大学大学院医学系研究科博士課程修了、医学博士授与

職歴：

1991年～1992年大阪大学医学部附属病院　第二外科

1992年～1995年大阪府立成人病センター病院外科

1999年～2006年関西労災病院外科・乳腺外科

2007年～現在相原病院 乳腺科

職位：　　　　理事長

所属学会等：

箕面市医師会　理事

大阪府医師会代議員

日本乳癌学会（乳腺専門医・指導医・評議員）

　・診療ガイドライン小委員会薬物療法委員(2003-2016)

　・診療ガイドライン小委員会薬物療法副委員長(2012-2014)

　・診療ガイドライン小委員会薬物療法委員長(2014-2016)

　・財務委員会委員(2012-2016)

　・臨床試験小委員会委員(2013-2016)

　・新専門医制度小委員会委員(2016-2022)

　・臨床試験研究委員会委員(2016-2018)

　・学術総会あり方委員会委員(2018-2022)

　・選挙委員会委員(2022-)

　・保険診療委員会委員(2022-)

　・地域医療・診療向上委員会委員（副委員長） (2022-)

日本外科学会(1991-)（認定医・専門医・指導医）

日本乳房オンコプラスティックサージャリー学会(評議員 2012-)

日本癌治療学会(1991-)

日本癌学会

日本臨床腫瘍学会

米国臨床腫瘍学会(2001-)

資格：マンモグラフィ検診精度管理中央委員会検診読影認定A判定

賞罰：

1994年大阪対癌協会助成金

1999年兵庫健康財団癌研究助成金

2002年社団法人医学振興銀杏会：地域医療に関する研究助成金

2002年第五回乳癌学会久野賞

2006年　日本乳癌学会研究奨励賞

発表論文（筆頭）

1　Aihara T, Noguchi S, Sasaki Y, Nakano H, Imaoka S. Clonal analysis of regenerative nodules in hepatitis C virus-induced liver cirrhosis.

Gastroenterology 1994;107(6):1805-11.

2　Aihara T, Furukawa H, Hiratsuka M, Iwanaga T, Imaoka S, Ishikawa O, Kabuto T, Sasaki Y, Kameyama M, Ohigashi H, Nakamori S. Lengthy survival of peritoneal recurrence for advanced gastric cancer after extended operation. Gann-no-seizonjikan-kenkyukaishi 　1994;14:71-74(in Japanese).

3　Aihara T, Umeshita K, Monden M, Kanai T, Goto M, Sakon K, Mori T, Wakasa K, Sakurai M. A resected case of focal fatty liver-With special reference to differential diagnosis from hepatocellular carcinoma with fatty infiltration. Nihon-Rinsho-Geka-Igakukaizassi 1994;55(3):693-697(in Japanese).

4　Aihara T, Kabuto T, Imaoka S, Furukawa H, Ishikawa O, Sasaki Y, Kameyama M, Taniguchi M, Koyama H, Iwanaga T.A case report of sinchronous esophageal carcinoma and renal cell carcinoma. Nihon-Rinsho-Geka-Igakukaizassi 1994;55(7):1780-1784(in Japanese).

5　Aihara T, Noguchi S, Sasaki Y, Nakano H, Monden M, Imaoka S. Clonal analysis of precancerous lesion of hepatocellular carcinoma.

Gastroenterology 1996;111(2):455-61.

6　Aihara T, Noguchi S, Ishikawa O, Furukawa H, Hiratsuka M, Ohigashi H, Nakamori S, Monden M, Imaoka S.Detection of pancreatic and gastric cancer cells in peripheral and portal blood by amplification of keratin 19 mRNA with reverse transcriptase-polymerase chain reaction.

Int J Cancer 1997;72(3):408-11.

7　Aihara T, Miyoshi Y, Nakamura Y. Hepatocellular carcinoma. Tanpakushitsu Kakusan Koso 1997;42(10 Suppl):1747-53(in Japanese).

8　Aihara T, Noguchi S, Sasaki Y, Nakano H, Monden M, Imaoka S. Differentiation of multifocal and multicentric hepatocellular carcinomas by DNA fingerprint analysis: case report. Surgery 1997;121(6):711-4.

9　Aihara T, Miyoshi Y, Koyama K, Suzuki M, Takahashi E, Monden M, Nakamura Y. Cloning and mapping of SMARCA5 encoding hSNF2H, a novel human homologue of Drosophila ISWI. Cytogenet Cell Genet1998;81(3-4):191-3.

10　Aihara T, Noguchi S, Miyoshi Y, Nakano H, Sasaki Y, Nakamura Y, Monden M, Imaoka S. Allelic imbalance of insulin-like growth factor II gene expression in cancerous and precancerous lesions of the liver. Hepatology 1998;28(1):86-9.

11　Aihara T, Fujiwara Y, Ooka M, Sakita I, Tamaki Y, Monden M. Mammaglobin B as a novel marker for detection of breast cancer micrometastases in axillary lymph nodes by reverse transcription-polymerase chain reaction. Breast Cancer Res Treat 1999;58(2):137-40.

12　Aihara T, Fujiwara Y, Miyake Y, Okami J, Okada Y, Iwao K, Sugita Y, Tomita N, Sakon M, Shiozaki H, Monden M. Mammaglobin B gene as a novel marker for lymph node micrometastasis in patients with abdominal cancers. Cancer Lett 2000;150(1):79-84.

13　Aihara T, Kim Y, Takatsuka Y. Phase II study of weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 2002;13(2):286-92.

14　Aihara T, Takatsuka Y, Itoh K, Sasaki Y, Katsumata N, Watanabe T, Noguchi S, Horikoshi N, Tabei T, Sonoo H, Hiraki S, Inaji H. Phase II study of concurrent administration of doxorubicin and docetaxel as first-line chemotherapy for metastatic breast cancer. Oncology 2003;64(2):124-30.

15　Aihara T, Takatsuka Y.Dye-guided sentinel node biopsy revisited; validation and observational study from a single institute.Breast Cancer2003;10(3):254-9.

16　Aihara T, Munakata S, Morino H, Takatsuka Y.Touch imprint cytology and immunohistochemistry for the assessment of sentinel lymph nodes in patients with breast cancer.Eur J Surg Oncol2003 ;29(10):845-8.

17　Aihara T, Munakata S, Morino H, Takatsuka Y.Feasibility of sentinel node biopsy for breast cancer after neoadjuvant endocrine therapy: a pilot study.J Surg Oncol　2004 ;85(2):77-81.

18　Aihara T, Munakata S, Morino H, Takatsuka Y. Comparison of frozen section and touch imprint cytology for evaluation of sentinel lymph node metastasis in breast cancer. Ann Surg Oncol 2004;11(8):747-50.

19　Aihara T, Takatsuka Y, Ohsumi S, Aogi, K, Hozumi Y, Imoto S, Mukai H, Iwata H, Watanabe T, Shimizu C, Nakagami K, Tamura M, Ito T, Masuda N, Ogino N, Hisamatsu K, Mitsuyama S, Abe H, Tanaka S, Yamaguchi T, Ohashi Y. Phase III Randomized Adjuvant Study of Tamoxifen Alone Versus Sequential Tamoxifen and Anastrozole in Japanese Postmenopausal Women with Hormone-Responsive Breast Cancer: N-SAS BC03 Study. Breast Cancer Research and Treatment 2010;121(2):379-87.

20　Aihara T, Suemasu K, Takei H, Hozumi Y, Takehara M, Saito T, Ohsumi S, Masuda N, Ohashi Y. Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients:results of N-SAS BC 04, the TEAM Japan substudy. Oncology2010;79(5-6):376-81.

21　Aihara T, Mukai H. The current status and future perspectives of CSPOR-BC.Breast Cancer2013;20(4):287-90.

22　Aihara T, Tanaka S, Sagara Y, Iwata H, Hozumi Y, Takei H, Yamaguchi H, Ishitobi M, Egawa C. Incidence of contralateral breast cancer in Japanese patients with unilateral minimum-risk primary breast cancer, and the benefits of endocrine therapy and radiotherapy.Breast Cancer 2014;21(3):284-91.

23　Aihara T, Yokota I, Hozumi Y, Aogi K, Iwata H, Tamura M, Fukuuchi A, Makino H, Kim R, Andoh M, Tsugawa K, Ohno S, Yamaguchi T, Ohashi Y, Watanabe T, Takatsuka Y, Mukai H.Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial.Breast Cancer Res Treat2014;148(2):337-43.

24　Aihara T, Toyama T, Takahashi M, Yamamoto Y, Hara F, Akabane H, Fujisawa T, Ishikawa T, Nagai S, Nakamura R, Tsurutani J, Ito Y, Mukai H.　The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition.　Breast Cancer. 2016 ;23(3):329-42.

25　Aihara T, et al. Prognosis and Effectiveness of Chemotherapy for Medullary Breast Carcinoma. Breast Cancer Res Treat, 2022;196(3):635-645..

発表論文（共著）

1　Noguchi S, Aihara T, Koyama H, Motomura K, Inaji H, Imaoka S, Wada A. Preoperative discrimination of fibroadenoma which is clinically and cytologically indistinguishable from breast carcinoma through clonal analysis of fine needle aspirate of tumor: Report of a case. Breast Cancer 1994;1(1):37-42.

2　Noguchi S, Aihara T, Motomura K, Inaji H, Koyama H. Clonal analysis of human breast tumors by means of polymerase chain reaction. Gan To Kagaku Ryoho 1994;21 Suppl 2:164-7(in Japanese).

3　Noguchi S, Aihara T, Koyama H, Motomura K, Inaji H, Imaoka S. Discrimination between multicentric and multifocal carcinomas of the breast through clonal analysis. Cancer 1994;74(3):872-7.

4　Noguchi S, Aihara T, Nakamori S, Motomura K, Inaji H, Imaoka S, Koyama H. The detection of breast carcinoma micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Cancer 1994;74(5):1595-600.

5　Kodama K, Doi O, Higashiyama M, Yokouchi H, Aihara T, Ueda T. A new approach for performing a one-stage operation through the mediastinum to resect bilateral lung metastases: report of a case. Surg Today 1995;25(3):275-7.

6　Noguchi S, Aihara T, Motomura K, Inaji H, Imaoka S, Koyama H, Tanaka H. Demonstration of polyclonal origin of giant fibroadenoma of the breast. Virchows Arch 1995;427(3):343-7.

7　Noguchi S, Yokouchi H, Aihara T, Motomura K, Inaji H, Imaoka S, Koyama H. Progression of fibroadenoma to phyllodes tumor demonstrated by clonal analysis. Cancer 1995;76(10):1779-85.

8　Noguchi S, Aihara T, Koyama H, Motomura K, Inaji H, Imaoka S. Clonal analysis of benign and malignant human breast tumors by means of polymerase chain reaction. Cancer Lett 1995;90(1):57-63.

9　Noguchi S, Aihara T, Motomura K, Inaji H, Imaoka S, Koyama H. Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Comparison between MUC1 mRNA and keratin 19 mRNA amplification. Am J Pathol 1996;148(2):649-56.

10　Noguchi S, Aihara T, Motomura K, Inaji H, Koyama H. Detection of breast cancer micrometastases in lymph nodes by amplification of keratin 19 mRNA with reverse-transcriptase polymerase chain reaction. Gan To Kagaku Ryoho 1996;23 Suppl 1:50-5(in Japanese).

11　Noguchi S, Aihara T, Motomura K, Inaji H, Imaoka S, Koyama H, Kasugai T, Wada A. Phyllodes Tumor of the Breast: Pathology, Histogenesis, Diagnosis, and Treatment. Breast Cancer 1996;3(2):79-92.

12　Noguchi S, Aihara T, Yoshino K, Motomura K, Inaji H, Imaoka S, Koyama H. Demonstration of monoclonal origin of human parotid gland pleomorphic adenoma. Cancer 1996;77(3):431-5.

13　Noguchi S, Aihara T, Motomura K, Inaji H, Imaoka S, Koyama H. Histologic characteristics of breast cancers with occult lymph node metastases detected by keratin 19 mRNA reverse transcriptase-polymerase chain reaction. Cancer 1996;78(6):1235-40.

14　Noguchi S, Hiratsuka M, Furukawa H, Aihara T, Kasugai T, Tamura S, Imaoka S, Koyama H, Iwanaga T. Detection of gastric cancer micrometastases in lymph nodes by amplification of keratin 19 mRNA with reverse transcriptase-polymerase chain reaction. Jpn J Cancer Res 1996;87(6):650-4.

15　Miyoshi Y, Iwao K, Nagasawa Y, Aihara T, Sasaki Y, Imaoka S, Murata M, Shimano T, Nakamura Y. Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res 1998;58(12):2524-7.

16　Takemasa I, Yamamoto H, Sekimoto M, Ohue M, Noura S, Miyake Y, Matsumoto T, Aihara T, Tomita N, Tamaki Y, Sakita I, Kikkawa N, Matsuura N, Shiozaki H, Monden M. Overexpression of CDC25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma.

Cancer Res 2000;60(11):3043-50.

17　Ooka M, Sakita I, Fujiwara Y, Tamaki Y, Yamamoto H, Aihara T, Miyazaki M, Kadota M, Masuda N, Sugita Y, Iwao K, Monden M. Selection of mRNA markers for detection of lymph node micrometastases in breast cancer patients. Oncol Rep 2000;7(3):561-6.

18　Kanyama H, Tomita N, Yamano T, Aihara T, Miyoshi Y, Ohue M, Sekimoto M, Sakita I, Tamaki Y, Kaneda Y, Senter PD, Monden M. Usefulness of repeated direct intratumoral gene transfer using hemagglutinating virus of Japan-liposome method for cytosine deaminase suicide gene therapy. Cancer Res 2001;61(1):14-8.

19　Munakata S, Aihara T, Morino H, Takatsuka Y. Application of immunofluorescence for intraoperative evaluation of sentinel lymph nodes in patients with breast carcinoma. Cancer. 2003 ;98(8):1562-8.

20　Miki H, Tamura S, Wada H, Kozuma Y, Kittaka N, Kim T, Takiuchi D, Aihara T, Sugimoto K, Fukunaga M, Ozato H, Tomita N, Takatsuka Y. A case of gastric cancer with peritoneal dissemination which showed the intraperitoneal CR by administrating TS-1 orally and paclitaxel intraperitoneally. Gan To Kagaku Ryoho2003;30(11):1661-4. (In Japanese)

21　Tomita N, Fukunaga M, Ohzato H, Tamura S, Sugimoto K, Aihara T, Miki H, Takatsuka Y, Matsuura N, Iwanaga T, Fukayama N, Sugano K. The novel germline mutation of hMSH2 gene in a case of a hereditary non-polyposis colorectal cancer (HNPCC) patient who meets the revised Amsterdam criteria.Jpn J Clin Oncol 2003;33(9):486-9.

22　Tomita N, Fukunaga M, Okamura S, Nakata K, Ohzato H, Tamura S, Sugimoto K, Aihara T, Miki H, Takatsuka Y, Matsuura N, Ishikawa H, Iwanaga T, Fukayama N, Sugano K.The novel germline mutation of the hMLH1 gene in a case of suspected hereditary non-polyposis colorectal cancer (HNPCC) in a patient with no family history of cancer. Jpn J Clin Oncol2004 ;34(9):556-60.

23　Taguchi T, Aihara T, Takatsuka Y, Shin E, Motomura K, Inaji H, Noguchi S.Phase II study of weekly paclitaxel for docetaxel-resistant metastatic breast cancer in Japan. Breast J 2004;10(6):509-13.

24　Hayakawa M, Aihara T, Takatsuka Y. The marriage, pregnancy, childbirth on the breast cancer--psychologic care. Nippon Rinsho 2006;64(3):575-80(in Japanese).

25　Ohsumi S, Shimozuma K, Ohashi Y, Shinji M, Hozumi Y, Mukai H, Takatsuka Y, Aihara T. Health-related quality of life and psychological distress of breast cancer patients after surgery during a phase III randomized trial comparing continuation of tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1-4 years: N-SAS BC 03. Breast Cancer Res Treat 2011;127(1):143-52.

26　Hozumi Y, Suemasu K, Takei H, Aihara T, Takehara M, Saito T, Ohsumi S, Masuda N, Ohashi Y. The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study.Ann Oncol2011;22(8):1777-82.

27　Oyama A, Ueno T, Uchiyama S, Aihara T, Miyake A, Kondo S, Matsunaga K.The effects of natural S-equol supplementation on skin aging in postmenopausal women: a pilot randomized placebo-controlled trial.Menopause 2012;19(2):202-10.

28　Miyake T, Aihara T, Noguchi S.Diagnosis of metachronous bilateral breast cancer."

Nihon Rinsho" 2012;70 Suppl 7:284-7. (in Japanese)

29　Kimura K, Iwamoto M, Tanaka S, Watanabe T, Aihara T, Sugimoto T, Miyara K, Hayashi M, Kouno T, Baba S, Kawashima H, Hashimoto N, Uchiyama K. Is the LHRH Agonist Recommended for Fertility Preservation ?. Gan To Kagaku Ryoho. 2015 ;42(8):1019-21. (in Japanese).

30　Dowsett M, Forbes JF, Bradley R, Ingle J, Aihara T, Bliss J, Boccardo F, Coates A, Coombes RC, Cuzick J, Dubsky P, Gnant M, Kaufmann M, Kilburn L, Perrone F, Rea D, Thürlimann B, van de Velde C, Pan H, Peto R, Davies C, Gray R.　Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.　 Lancet. 2015;386(10001):1341-52.

31　Hara F, Takashima T, Tsurutani J, Saito T, Taira N, Kashiwabara K, Aihara T, Mukai H. 　J Clin Trials 2016, 6:3. Randomized, Optimal Dose Finding, Phase Ii Study of Tri-Weekly Nab-Paclitaxel in Patients with Metastatic Breast Cancer (ABROAD).

32　Shimoi T, Shimomura A, Shien T, Uemura Y, Kato H, Kitada M, Toyama T, Aihara T, Mukai H. Open-label Phase II study of everolimus plus endocrine therapy in postmenopausal women　with ER-positive and HER2-negative metastatic　breast cancer (Chloe trial). Open Access Journal of Clinical Trials 2018:10 13–18

33　Iwamoto T, Taira N, Fujisawa T, Araki K, Sakamaki K, Sangai T, Kikawa Y, Shien T, Takao S, Sato M, Goto Y, Yoshida T, Takahashi M, Aihara T, Mukai H.　Hormonal Therapy Resistant Estrogen-receptor Positive Metastatic Breast Cancer Cohort (HORSE-BC) Study : Current Status of Treatment Selection in Japan. Acta Med Okayama. 2018 Aug;72(4):369-374.

34　Iwamoto T, Fujisawa T, Shien T, Araki K, Sakamaki K, Sangai T, Kikawa Y, Takao S, Nishimura R, Takahashi M, Aihara T, Mukai H, Taira N. The efficacy of sequential second-line endocrine therapies (ETs) in postmenopausal estrogen receptor-positive and HER2-negative metastatic breast cancer patients with lower sensitivity to initial ETs. Breast Cancer. 2020 Sep;27(5):973-981.

35　Tsurutani J, Hara F, Kitada M, Takahashi M, Kikawa Y, Kato H, Sakata E, Naito Y, Hasegawa Y, Saito T, Iwasa T, Taira N, Takashima T, Kashiwabara K, Aihara T, Mukai H.　 Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer. Breast. 2021 Feb;55:63-68.

36　Ishikawa T, Sakamaki K, Narui K, Nishimura H, Sangai T, Tamaki K, Hasegawa Y, Watanabe KI, Suganuma N, Michishita S, Sugae S, Aihara T, Tsugawa K, Kaise H, Taira N, Mukai H. Prospective cohort study of febrile neutropenia in breast cancer patients administered with neoadjuvant and adjuvant chemotherapies: CSPOR-BC FN study. Breast. 2021 Apr;56:70-77.

37　Taira N, Kashiwabara K, Tsurutani J, Kitada M, Takahashi M, Kato H, Kikawa Y, Sakata E, Naito Y, Hasegawa Y, Saito T, Iwasa T, Takashima T, Aihara T, Mukai H, Hara F.　 Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.　Breast Cancer. 2022 Jan;29(1):131-143.

38　Miyahara K, Narui K, Uemura Y, Yamada A, Araki K, Fujisawa F, Nakayama T, Ishikawa T, Taira N, Kikawa Y, Aihara T, Mukai H.　Prospective Cohort Study of Combination Therapy With Abemaciclib and Hormonal Therapy for Chemotherapy-Treated Patients With Hormone Receptor-Positive Metastatic Breast Cancer.　World J Oncol. 2022 Aug;13(4):216-221.

39　Kikawa Y, Hagiwara Y, Fujisawa T, Araki K, Iwamoto T, Sangai T, Shien T, Takao S, Nishimura R, Takahashi M, Toyama T, Aihara T, Mukai H, Taira N. Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapy. PLoS One. 2022;17(11):e0278344.

40　Abe Y, Taira N, Kashiwabara K, Tsurutani J, Kitada M, Takahashi M, Kato H, Kikawa Y, Sakata E, Naito Y, Hasegawa Y, Saito T, Iwasa T, Takashima T, Aihara T, Mukai H, Hara F, Shien T, Doihara H, Toyooka S. Association of Genetic Polymorphism with Taxane-induced Peripheral Neuropathy: Sub-analysis of a Randomized Phase II Study to Determine the Optimal Dose of 3-week Cycle Nab-Paclitaxel in Metastatic Breast Cancer Patients. Acta Med Okayama. 2022;76(6):661-671.

41　 Early Breast Cancer Trialists’ Collaborative Group. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials. Lancet. 2023;401(10384):1277-1292.